MedPath

Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）

Generic Name
Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）

Overview

No overview information available.

Indication

用于：1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染； 2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥； 3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员； 4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少； 5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。

Associated Conditions

No associated conditions information available.

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

Title
Posted
Study ID
Phase
Status
Sponsor
PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.
2022/09/07
NCT05530200
Phase 2
Not yet recruiting
Second Affiliated Hospital of Soochow University
ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab
2022/05/09
NCT05366062
Phase 2
Not yet recruiting
Epitopoietic Research Corporation
Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection
2022/04/01
NCT05307835
Phase 1
Recruiting
Second Affiliated Hospital, School of Medicine, Zhejiang University
Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
2022/03/23
NCT05292417
Phase 2
UNKNOWN
The First Affiliated Hospital of Xiamen University
GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS
2022/03/04
NCT05266001
Phase 3
Terminated
Nationwide Children's Hospital
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
2021/06/23
NCT04936529
Phase 2
Recruiting
Memorial Sloan Kettering Cancer Center
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
2021/06/01
NCT04909515
Phase 2
Withdrawn
Y-mAbs Therapeutics
Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
2021/05/19
NCT04892498
Phase 2
UNKNOWN
Second Affiliated Hospital of Soochow University
IBI188 Combination Therapy in Solid Tumors
2021/04/27
NCT04861948
Phase 1
Terminated
Innovent Biologics (Suzhou) Co. Ltd.
Metastatic Solid Cancer Clinical Trial
2021/02/04
NCT04739618
Phase 2
Active, not recruiting
ImmunSYS, LLC

FDA Drug Approvals

View More FDA Approvals

Sign in to access additional FDA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

View More EMA Approvals

Sign in to access additional EMA-approved drug information with detailed regulatory data.

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Sign in to access additional HSA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

View More NMPA Approvals

Sign in to access additional NMPA-approved drug information with detailed regulatory data.

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Sign in to access additional PPB-approved drug information with detailed regulatory data.

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

View More TGA Approvals

Sign in to access additional TGA-approved drug information with detailed regulatory data.

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

View More Health Canada Approvals

Sign in to access additional Health Canada approved drug information with detailed regulatory data.

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

View More CIMA AEMPS Approvals

Sign in to access additional CIMA AEMPS approved drug information with detailed regulatory data.

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

View More Philippines FDA Approvals

Sign in to access additional Philippines FDA approved drug information with detailed regulatory data.

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

View More Saudi SFDA Approvals

Sign in to access additional Saudi SFDA approved drug information with detailed regulatory data.

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

View More Malaysia NPRA Approvals

Sign in to access additional Malaysia NPRA approved drug information with detailed regulatory data.

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

View More UK EMC Drug Information

Sign in to access additional UK EMC drug information with detailed pharmaceutical data.

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.